$100 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth This Much Today
Horizon Therapeutics (NASDAQ:HZNP) has outperformed the market over the past 10 years by 36.9% on an annualized basis…
A Bullish Sign Appears On Horizon Therapeutics’s Chart
If history is any guide, there may be good fortune ahead for shares of Horizon Therapeutics (NASDAQ:HZNP). A…
Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies.
Analyzing Horizon Therapeutics’s Short Interest
Horizon Therapeutics's (NASDAQ:HZNP) short percent of float has fallen 7.07% since its last report. The company recently reported that it has 6.49 million shares sold short, which is 2.89% of all regular shares that are available for trading.
UPLIZNA Approved In Brazil For The Treatment Of Neuromyelitis Optica Spectrum Disorder
-- First and only anti-CD19 B-cell-depleting monotherapy for the treatment of adult patients with NMOSD who are anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+) --
-- NMOSD is a devastating rare
Benzinga’s Top Ratings Upgrades, Downgrades For December 13, 2022
Upgrades For Equinix Inc (NASDAQ:EQIX), Cowen & Co. upgraded the previous rating of Market Perform to Outperform. In…
BMO Capital Downgrades Horizon Therapeutics to Market Perform
BMO Capital analyst Gary Nachman downgrades Horizon Therapeutics (NASDAQ:HZNP) from Outperform to Market Perform.
Guggenheim Downgrades Horizon Therapeutics to Neutral, Raises Price Target to $116.5
Guggenheim analyst Yatin Suneja downgrades Horizon Therapeutics (NASDAQ:HZNP) from Buy to Neutral and raises the price target from $98 to $116.5.
SVB Leerink Downgrades Horizon Therapeutics to Market Perform, Raises Price Target to $116.5
SVB Leerink analyst David Risinger downgrades Horizon Therapeutics (NASDAQ:HZNP) from Outperform to Market Perform and raises the price target from $88 to $116.5.
Wells Fargo Downgrades Horizon Therapeutics to Equal-Weight, Lowers Price Target to $116.5
Wells Fargo analyst Derek Archila downgrades Horizon Therapeutics (NASDAQ:HZNP) from Overweight to Equal-Weight and lowers the price target from $118 to $116.5.